Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 15-16/2020

08.07.2020 | original article

REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer

verfasst von: Dr. Gudrun Piringer, Laurenz Vormittag, Leopold Öhler, Birgit Grünberger, Johannes Meran, Marlies Moshammer, Johannes Andel, Wolfgang Eisterer, Vera Trommet, Josef Thaler

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

A frequent side effect of the multikinase inhibitor regorafenib is fatigue. Physical activity has shown potential in reducing cancer-related fatigue.

Methods

This non-interventional pilot study assessed physical activity levels of metastatic colorectal cancer (mCRC) patients treated with regorafenib based on median daily step counts measured at 1‑week intervals using a pedometer. The study further evaluated relations between physical activity levels and fatigue, quality of life (QoL) and progression-free survival.

Results

Pedometer data were available for 22 out of 25 enrolled patients. The numbers of days with available pedometer data ranged from 6 to 100 days. The overall median daily step count was 2357 (range 10–14,931), with substantial interindividual and intraindividual variations. Interindividual median weekly step counts were in the range of 5000–7000 in some, 2000–3000 in others, and several hundreds or less in a few patients. Intraindividual daily step counts also varied by several thousands of steps. Step counts in weeks in which patients reported fatigue were well within the range of or even higher than step counts in adjacent weeks, indicating a lack of correlation. The risk of disease progression was also independent of median weekly step counts; however, significant correlations were seen between QoL and step counts.

Conclusion

Despite the severity of their disease patients showed remarkable levels of walking activity. In view of the highly individual activity levels, exercise prescriptions for seriously ill patient populations should be personalized to the specific needs and preferences of each individual patient.
Literatur
6.
26.
Zurück zum Zitat Courneya KS, Friedenreich CM, Quinney HA, et al. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care. 2003;12(4):347–57. CrossRef Courneya KS, Friedenreich CM, Quinney HA, et al. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care. 2003;12(4):347–57. CrossRef
28.
Zurück zum Zitat Cooke AB, Pace R, Chan D et al. (2018) A qualitative evaluation of a physician-delivered pedometer-based step count prescription strategy with insight from participants and treating physicians. Diabetes Res Clin Pract. 2018;139:314–22. CrossRef Cooke AB, Pace R, Chan D et al. (2018) A qualitative evaluation of a physician-delivered pedometer-based step count prescription strategy with insight from participants and treating physicians. Diabetes Res Clin Pract. 2018;139:314–22. CrossRef
Metadaten
Titel
REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer
verfasst von
Dr. Gudrun Piringer
Laurenz Vormittag
Leopold Öhler
Birgit Grünberger
Johannes Meran
Marlies Moshammer
Johannes Andel
Wolfgang Eisterer
Vera Trommet
Josef Thaler
Publikationsdatum
08.07.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01703-z